{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Best response, CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Best response, PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Best response, SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Best response, SD/PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Best response, PD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Best response, NE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Clinical Response, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Clinical Response, No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Disease control, Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Disease control, No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Best response was recorded from the start of treatment until disease progression. Response assessment was essentially based on a set of measurable lesions (target lesions \\[TL\\]), and any other lesions (non-target lesions \\[NTL\\]), both identified at baseline. Complete Response (CR)=disappearance of all TL or NTL; Partial Response (PR) = at least 30 percent (%) decrease in the sum of the longest diameter(LD) of TL compared to baseline, stable disease (SD) = neither sufficient shrinkage to qualify PR nor sufficient increase to qualify for Progressive disease (PD) compared with baseline; PD = at least 20% increase in the sum of LD of TL compared with baseline, or the appearance of one or more new lesions, or both of these, and/or unequivocal progression of existing NTL; NE =non-evaluable; Clinical response: any CR or PR best overall response; Disease control: any CR, PR, SD or SD/PR best overall response.","groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"OG000","title":"NY-ESO 1 Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis was performed on the total treated cohort (TTC), which included all subjects who received at least one dose of the Antigen-Specific Cancer Immunotherapeutic (ASCI) treatment.","reportingStatus":"POSTED","timeFrame":"During the study treatment period (maximum duration = 49 months).","title":"Number of Patients With the Best Overall Response in the Overall Population","type":"PRIMARY","unitOfMeasure":"Participants"}